je.st
news
Home
› Oncolytics Biotech's REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer
Oncolytics Biotech's REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer
2015-02-17 15:06:44| Biotech - Topix.net
Oncolytics Biotech Inc. , a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer. "This is the second indication for which we have received Orphan Drug Designation in the United States," said Dr. Brad Thompson, President and CEO of Oncolytics.
Tags: treatment
drug
cancer
receives
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||